Global Hepatitis Testing/Diagnosis Market Size study & Forecast, by Test (Blood Test, Imaging Tests, Liver Biopsy), Technology (ELISA, Rapid Diagnostic Test, PCR), End-use and Regional Forecasts 2022-2032

The Global Hepatitis Testing/Diagnosis Market, valued at approximately USD 4.07 billion in 2024, is projected to grow at a promising CAGR of 6.50% during the forecast period 2025-2035. Hepatitis, a major public health challenge affecting millions globally, demands precise diagnostic solutions to curb its long-term health implications, such as liver cirrhosis and hepatocellular carcinoma. Testing methods—ranging from advanced molecular assays to rapid diagnostic kits—have evolved into indispensable tools for early detection, disease monitoring, and guiding therapeutic interventions. The surge in market demand is being propelled by rising infection rates, heightened public awareness, and the adoption of modern, highly sensitive technologies like polymerase chain reaction (PCR) and next-generation ELISA platforms. Governments, healthcare organizations, and private providers are increasingly prioritizing early detection strategies, while industry players are channeling investments into innovative, point-of-care solutions that ensure accessibility even in remote or resource-limited settings.

The momentum in this market is further reinforced by global health initiatives targeting hepatitis elimination, alongside the mounting integration of hepatitis testing into routine health check-ups, antenatal care, and blood bank screening protocols. According to WHO estimates, more than 350 million people live with chronic hepatitis B or C, and most remain undiagnosed, underscoring the critical need for scalable diagnostic infrastructure. The proliferation of rapid diagnostic tests and portable imaging systems has significantly improved screening penetration rates in developing regions, while high-income countries are focusing on advanced, lab-based PCR assays to refine accuracy and reduce turnaround times. However, the high cost of certain advanced diagnostic platforms, disparities in healthcare access, and the absence of robust screening policies in some nations continue to impede optimal market expansion.

North America currently leads the global hepatitis testing/diagnosis market, supported by comprehensive screening guidelines, strong insurance coverage, and a technologically advanced healthcare ecosystem. The U.S., in particular, benefits from continuous innovation, with biotech companies launching new-generation diagnostic assays to detect viral genotypes and quantify viral loads. Europe follows closely, driven by large-scale public health programs and cross-country collaborations to achieve WHO hepatitis elimination targets by 2030. Meanwhile, Asia Pacific is set to witness the fastest growth over the forecast period, fuelled by high disease prevalence in countries like China and India, expanding healthcare infrastructure, and intensified government-backed awareness campaigns. Latin America and the Middle East & Africa are also emerging as important growth corridors, propelled by donor-funded healthcare initiatives, increased diagnostic capacity, and international partnerships aimed at strengthening hepatitis control strategies.

Major market player included in this report are:
• Abbott Laboratories
• Siemens Healthineers AG
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Hologic, Inc.
• Quest Diagnostics Incorporated
• Ortho Clinical Diagnostics
• Sysmex Corporation
• Grifols, S.A.
• Becton, Dickinson and Company
• bioMérieux SA
• Cepheid, Inc.

Global Hepatitis Testing/Diagnosis Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Test:
• Blood Test
• Imaging Tests
• Liver Biopsy

By Technology:
• ELISA
• Rapid Diagnostic Test
• PCR

By End-use:
• Hospitals
• Diagnostic Laboratories
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe (ROE)

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific (RoAPAC)

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more